Latest News and Press Releases
Want to stay updated on the latest news?
-
– Presentations to highlight preclinical data supporting combination of KO-2806 with targeted therapies, including TKIs, KRASG12C inhibitors and KRASG12D inhibitors – SAN DIEGO, Oct. 04, 2023 ...
-
– Oral presentation at RAS Summit supports development of next-generation FTI in combination with KRASG12C inhibitors – – Company to include KRASG12C-mutant NSCLC in combination portion of Phase 1...
-
SAN DIEGO, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
-
SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
-
– Enrollment in registration-directed trial of ziftomenib in NPM1-mutant AML continues to outperform projections – – First patients dosed in combination study of ziftomenib in NPM1-mutant and...
-
SAN DIEGO, July 27, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
-
SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
-
SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
-
– 35% CR rate (7/20) among patients with relapsed/refractory NPM1-mutant AML treated at 600 mg dose (RP2D) – – 33% (2/6) of patients with FLT3 co-mutations and 50% (4/8) of patients with IDH...
-
– Late-breaking abstracts scheduled for publication on the EHA website at 16:00 CET on Thursday, June 1, 2023 – – Data from Phase 1 trial of ziftomenib to be presented at the late-breaking oral...